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Background: We have shown previously that extended intravenous antibiotic therapy is 
  associated with low morbidity and no mortality in patients referred for treatment of neurologic 
Lyme disease. In this study, we evaluated the benefit of extended intravenous antibiotic therapy 
in patients with symptoms of neurologic Lyme disease.
Methods: Patients with significant neurologic symptoms and positive testing for Borrelia 
  burgdorferi were treated with intravenous antibiotics, and biweekly evaluation of symptom 
severity was performed using a six-level ordinal scale. Four symptoms were selected a priori 
as primary outcome measures in the study, ie, fatigue, cognition, myalgias, and arthralgias. 
Patients were placed into five groups according to time on treatment (1–4, 5–8, 9–12, 13–24, 
and 25–52 weeks), and changes in the primary symptoms as a function of time on treatment 
were analyzed using a mixed-effects proportional odds model.
Results: Among 158 patients with more than one follow-up visit who were monitored for up to 
1 year, there were on average 6.7 visits per person (median 5, range 2–24). The last follow-up 
day was on average 96 days after enrollment (median 69, range 7–354 days), corresponding to 
the length of antibiotic therapy. Each primary symptom was significantly improved at one or 
more time points during the study. For cognition, fatigue, and myalgias, the greatest improve-
ment occurred in patients on the longest courses of treatment (25–52 weeks) with odds ratios 
(OR) for improvement of 1.97 (P = 0.02), 2.22 (P , 0.01), and 2.08 (P = 0.01), respectively. In 
contrast, arthralgias were only significantly improved during the initial 1–4 weeks of therapy 
(OR: 1.57, P = 0.04), and the beneficial effect of longer treatment did not reach statistical 
significance for this symptom.
Conclusion: Prolonged intravenous antibiotic therapy is associated with improved cognition, 
fatigue, and myalgias in patients referred for treatment of neurologic Lyme disease. Treatment 
for 25–52 weeks may be necessary to obtain symptomatic improvement in these patients.
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Introduction
Lyme disease caused by the spirochete Borrelia burgdorferi is the most common tick-
borne illness in the world today.1–4 Although prompt diagnosis and treatment results 
in a favorable outcome in patients with acute B. burgdorferi infection, tick exposure 
and acute infection with the Lyme spirochete often go unrecognized, and patients with 
untreated infection may go on to develop a chronic debilitating multisystem illness 
that is difficult to manage.1–4
The approach to the treatment of patients with persistent symptoms of Lyme   disease 
has been controversial. The International Lyme and Associated Diseases Society 
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(ILADS) advocates open-ended treatment linked to symptom 
resolution for what is considered to be a persistent spirochetal 
infection, claiming that the benefit of such treatment out-
weighs the risk.5 In contrast, the Infectious Diseases Society 
of America (IDSA) believes that persistent symptoms in these 
patients are due to “post-Lyme syndrome”, a noninfectious 
complication of acute spirochetal disease.6 According to the 
IDSA, treatment with prolonged antibiotics is considered 
inappropriate and even dangerous.6–10
In a previous prospective study, we showed that pro-
longed intravenous antibiotic therapy was associated with 
low   morbidity and no mortality in closely monitored patients 
referred for treatment of neurologic Lyme disease.11 We have 
now examined the benefit of this therapy in a similar cohort 
of patients with neurologic Lyme disease symptoms.
Materials and methods
Patients
From April 2008 through August 2009, 225 consecutive 
patients were enrolled in this study. Patients from 18 states 
across the US were referred by their treating physicians to 
a single homecare company that administers intravenous 
antibiotic therapy in the outpatient setting. All patients had 
significant neuropsychiatric symptoms for at least 3 months 
and positive testing for B. burgdorferi, considered to be 
consistent with a diagnosis of neurologic Lyme disease by 
their treating physicians.11–14 Neuropsychiatric symptoms 
included Bell’s palsy, meningoradiculitis, migraine, enceph-
alopathy, mood disorders, and/or psychosis associated with 
tick exposure in a Lyme endemic area. Neurologic involve-
ment was confirmed with brain magnetic resonance imaging, 
single-photon emission computed tomographic brain scans, 
and/or formal neuropsychiatric evaluation.11–14 Serologic 
testing for B. burgdorferi was ordered and interpreted by 
the treating physicians.
Informed consent for intravenous antibiotic therapy and 
monitoring was obtained from all subjects, and the potential 
risks of extended parenteral therapy as well as the respon-
sibility of patients to comply with the homecare treatment 
protocols were clearly defined, as previously described.11 
Patients also agreed that information obtained from their 
treatment could be used for research purposes provided that 
strict confidentiality was maintained, as outlined in the guide-
lines of the US Department of Health and Human   Services 
for observational studies (http://www.hhs.gov/ohrp/irb/
irb_guidebook.htm). Consent forms acknowledging compli-
ance with the Patient Bill of Rights and the Health Insurance 
Portability and Accountability Act guidelines were signed by 
all patients or their legal guardians. The study was granted 
exemption from review under 45 CFR 46.101(b)(4) by the 
Western Institutional Review Board, Olympia, WA, because 
it involved collection of data “in such a manner that subjects 
cannot be identified directly or through identifiers linked to 
the subjects”.
Treatment protocol
Intravenous antibiotics were administered to all patients via 
an intravascular device using the SASH (saline/admixed 
drug/saline/heparin) protocol.11 This protocol involves initial 
infusion of a 10 mL normal saline flush to clear the line, then 
administration of the antibiotic in normal saline followed by a 
second 10 mL normal saline flush, and then 5 mL of heparin 
(100 units/mL) to maintain intravascular device   patency. 
Dressing change and intravascular device assessment were 
performed on a weekly basis by homecare nurses, with 
monitoring for medication reactions and intravascular device 
infection, clotting, or infiltration according to the standard 
homecare protocol. Medication-related and catheter-related 
complications were immediately reported to the treating phy-
sician and the homecare service, and appropriate measures 
were taken to deal with the complication.
For the purpose of this study, only patients receiving intra-
venous ceftriaxone were included in the analysis. Patients 
with allergy to ceftriaxone were excluded from the study, and 
the ceftriaxone dose was determined by the treating   physician. 
Patients on ceftriaxone therapy had liver function testing 
performed every 2 weeks, and ursodiol therapy was offered 
in conjunction with this antibiotic to prevent   gallbladder 
toxicity. Probiotic therapy with daily oral acidophilus and/or 
saccharomyces was routinely recommended to all patients 
to prevent Clostridium difficile enterocolitis, as previously 
described.11 Ursodiol and probiotic therapy were dosed 
according to the manufacturer’s recommendations.15,16
Outcome measures
All patients completed a biweekly monitoring tool that 
assessed three broad symptom complexes, ie, pain, neurologic 
function, and general symptoms. The monitoring tool was 
developed during the previous safety study11 and contained 
questions about 28 separate symptoms. Participants were 
asked to rate each symptom’s severity and impact on their 
daily life as one of six ordinal classes, ie, 0 = not affected, 
1 = slight, barely noticeable problem, 2 = minor yet notice-
able problem, 3 = moderate problem, interferes with some 
daily activities, 4 = major problem, interferes with most daily 
activities, and 5 = disabling problem. Aside from measuring International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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symptomatic changes, the use of the monitoring tool had two 
additional purposes, ie, to determine which symptoms caused 
the most functional disability and to mask the most significant 
symptoms in order to avoid response bias on the part of study 
participants who might focus on these symptoms.
Four symptoms were selected a priori as primary outcome 
measures in the study, and changes during treatment in these 
outcome measures were evaluated, ie, fatigue, cognition 
(“brain fog”), myalgias (muscle aches), and arthralgias (joint 
pain). These four symptoms comprised the most disabling 
factors for patients based on levels 4 and 5 ratings in the previ-
ous study. Questioning about these symptoms was   randomly 
mixed with other questions in the monitoring tool.
Statistical analysis
Changes in the primary outcome measures as a function 
of time on treatment were analyzed using a mixed-effects 
proportional odds model (also referred to as a mixed-effects 
cumulative logit model), with measurement times nested 
within each participant.17 For each outcome, the validity of 
the proportional odds assumption was evaluated by fitting 
five mixed-effects binomial logistic models, categorizing 
the outcomes as 0 or 1, with each level used as a threshold, 
ie, 0 vs $1, #1 vs $2, #2 vs $3, #3 vs $4, and #4 vs 5. 
The log odds of the effects from each of the five models 
were examined using the point estimate and 95% confi-
dence interval (CI). If the log odds for all of the five models 
appeared similar, then the proportional odds assumption was 
determined to represent the data well. If one or two models 
for a specific outcome had very different log odds, the ordinal 
classes were combined such that this assumption was met. If 
the assumption was not met, the model was not fit.
Each participant was placed into one of the five strata, 
based on duration of intravenous antibiotic treatment, and 
separate treatment effects were estimated for each patient 
stratum. Patient strata were 1–4 weeks (n = 32), 5–8 weeks 
(n = 33), 9–12 weeks (n = 28), 13–24 weeks (n = 37), and 
25–52 weeks (n = 28) on intravenous therapy, resulting in 
patient groups with similar numbers of participants. To relax 
assumptions about the functional form of the relationship 
between treatment duration and symptom severity, time 
on intravenous treatment was categorized as 0–1 week, 
1–4 weeks, 5–8 weeks, 9–12 weeks, 13–24 weeks, and 
25–52 weeks. Treatment effectiveness by patient stratum 
expressed as the conditional odds and 95% CI of being in a 
lower (less severe) class are presented comparing responses 
during the final period of intravenous treatment with 
responses from first week on treatment.
The Akaike information criterion was used to measure the 
relative goodness of fit of the statistical model.18 Three models 
were fitted to each outcome, and the result of the model with 
the lowest Akaike information criterion is presented. The 
three models include a factor variable for time on treatment, 
factors for time on treatment and patient stratum, and factors 
for time on treatment, patient stratum, and their interaction. 
The best model was confirmed using likelihood ratio tests.
Statistical analysis was performed using R 2.12.2   software 
(R Foundation for Statistical Computing, Vienna, Austria), 
and two-sided P values less than 0.05 were considered to be 
statistically significant.
Results
A total of 225 participants were initially enrolled in the study. 
In order to ensure treatment uniformity, only ceftriaxone-
treated subjects with more than one visit over at least 1 week 
and up to 1 year of follow-up were included in the analysis. 
There were 158 patients who met these criteria (32 men and 
126 women) accounting for 1051 study visits. The mean 
patient age was 41.1 (range 15–67) years. There were on 
average 6.7 visits (median 5, range 2–24) per person. The 
last follow-up day was on average 96 days after enrollment 
(median 69, range 7–354 days), corresponding to the length of 
antibiotic therapy. The number of participants in each stratum, 
based on duration of treatment, was similar: 32 patients were 
on treatment 1–4 weeks, 33 for 5–8 weeks, 28 for 9–12 weeks, 
37 for 13–24 weeks, and 28 for 25–52 weeks.
Baseline scores for all outcomes are shown in Table 1. The 
scores for the 28 symptoms varied significantly, with patients 
showing a predominance of neurologic symptoms (74% 
with scores . 0) over non-neurologic symptoms (65% with 
pain scores . 0, 52% with systemic symptom scores . 0). 
This symptom distribution was consistent with the clinical 
diagnosis of neurologic Lyme disease made by the treating 
physician. However, the four target symptoms made up 
the majority of significant (levels 4 and 5) severity scores 
at   baseline, ie, myalgias (41%), arthralgias (48%), fatigue 
(66%), and cognition (42%). Of the other 24 symptoms, 
only neck pain (37%), headache (35%), back pain (33%), 
and insomnia (32%) had similar severity scores.
The baseline symptom severity scores stratified by duration 
of time on treatment are presented in Table 2. A likelihood 
ratio test showed significant differences in baseline scores 
according to patient stratum for the fatigue measure, with 
those on treatment for 9–12 and 13–24 weeks presenting with 
worse fatigue than the other groups. Baseline scores for the 
other three primary outcomes were not significantly different   International Journal of General Medicine 2011:4
Table 1 Baseline values of symptom severity
  0 (not  
affected)
1 (slight, barely  
noticed)
2 (minor yet  
noticeable  
problem)
3 (moderate  
problem, interferes  
some daily activities)
4 (major problem  
interferes most  
daily activities)
5 (disabling   
problem)
Overall 8 (5%) 4 (2%) 15 (9%) 59 (36%) 60 (36%) 20 (12%)
Pain
Tender glands 106 (62%) 23 (13%) 13 (8%) 14 (8%) 13 (8%) 3 (2%)
Sore throat 107 (62%) 22 (13%) 20 (12%) 13 (8%) 6 (3%) 4 (2%)
Abdominal,  
testicular, pelvic
76 (44%) 25 (15%) 28 (16%) 18 (10%) 17 (10%) 8 (5%)
chest 100 (58%) 21 (12%) 20 (12%) 15 (9%) 9 (5%) 7 (4%)
Back 43 (25%) 11 (6%) 23 (13%) 38 (22%) 38 (22%) 19 (11%)
Muscles 32 (19%) 10 (6%) 22 (13%) 37 (22%) 50 (29%) 21 (12%)
headache 26 (15%) 19 (11%) 33 (19%) 35 (20%) 32 (19%) 27 (16%)
neck 33 (19%) 14 (8%) 18 (10%) 43 (25%) 36 (21%) 28 (16%)
Joints 18 (10%) 13 (8%) 20 (12%) 39 (23%) 50 (29%) 32 (19%)
Neurologic
Fatigue 4 (2%) 3 (2%) 12 (7%) 38 (22%) 61 (35%) 54 (31%)
numbness, tingling 45 (26%) 32 (19%) 32 (19%) 32 (19%) 21 (12%) 10 (6%)
Lightheadedness 27 (16%) 30 (18%) 42 (25%) 40 (23%) 19 (11%) 13 (8%)
Poor balance 29 (17%) 32 (19%) 37 (22%) 35 (20%) 21 (12%) 18 (10%)
Tremor 74 (43%) 26 (15%) 28 (16%) 17 (10%) 18 (10%) 9 (5%)
Skin sensitivity 70 (41%) 20 (12%) 25 (15%) 33 (19%) 14 (8%) 10 (6%)
Vision 65 (38%) 26 (15%) 30 (17%) 28 (16%) 12 (7%) 11 (6%)
Sound or light sensitivity 54 (32%) 18 (11%) 23 (13%) 37 (22%) 25 (15%) 14 (8%)
Tinnitus 66 (39%) 27 (16%) 30 (18%) 28 (16%) 11 (6%) 9 (5%)
cognition (“brain fog”) 28 (16%) 19 (11%) 20 (12%) 33 (19%) 44 (26%) 28 (16%)
Mood swings 33 (19%) 27 (16%) 36 (21%) 31 (18%) 29 (17%) 16 (9%)
Systemic
Bladder 102 (59%) 21 (12%) 19 (11%) 12 (7%) 11 (6%) 7 (4%)
Libido 82 (49%) 12 (7%) 13 (8%) 18 (11%) 14 (8%) 29 (17%)
Gastrointestinal 61 (36%) 29 (17%) 24 (14%) 29 (17%) 16 (9%) 12 (7%)
Shortness of breath 72 (42%) 20 (12%) 31 (18%) 28 (16%) 14 (8%) 5 (3%)
cough 108 (63%) 28 (16%) 13 (8%) 16 (9%) 5 (3%) 1 (1%)
heart palpitations 88 (51%) 24 (14%) 28 (16%) 19 (11%) 9 (5%) 4 (2%)
Sleeping a lot 111 (65%) 12 (7%) 10 (6%) 11 (6%) 16 (9%) 11 (6%)
Sleep difficulty 37 (22%) 16 (9%) 27 (16%) 38 (22%) 26 (15%) 27 (16%)
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by treatment duration. The proportional odds assumption 
appears to have been met for all models after combining the 
highest two ordinal classes for cognition and joint pain and/or 
the lowest two ordinal classes for cognition.
Table 3 shows the estimated changes in symptom sever-
ity at the end of treatment compared with the first week on 
treatment for each patient stratum. The severity of the four 
primary symptoms was significantly improved in at least one 
patient stratum (P , 0.05), and most P values were ,0.10 in 
all groups for arthralgias, myalgias, and fatigue. For myalgias, 
arthralgias, and cognition, the model with the lowest Akaike 
information criterion included only the factor representing 
time on treatment; for fatigue it included both treatment 
duration and patient stratum. Those in treatment weeks 1–4 
had significantly better arthralgia scores at the end of treat-
ment compared with baseline, with the odds of being in a 
less severe ordinal group 1.57 times greater at the end of 
treatment compared with baseline (95% CI: 1.02–2.4). This 
corresponds to a 19% decrease in the proportion of patients 
reporting severe or disabling arthralgias after 1–4 weeks 
and a 17% drop after 25–52 weeks of treatment compared 
with baseline. Although the odds ratios were similar for the 
other participant groups, the effects were only marginally 
significant (,0.10).
The severity of myalgias improved during the study as 
well, with more improvement seen in patients with longer 
duration of intravenous treatment. In those treated for 
25–52 weeks, the odds of being in a less severe ordinal 
group were 2.08 (1.2–3.50) times greater at the end of treat-
ment compared with baseline. This corresponds to about 
a 31% reduction in the proportion of patients reporting a 
major or disabling problem with myalgias (ordinal group 
4 or 5) after 25–52 weeks of treatment compared with 
baseline.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Baseline symptom severity for each follow-up duration group. Only those on follow-up of more than 1 week and less than 1 
year are included
Time on  
treatment
Not  
affected (0)
Slight, barely  
noticed (1)
Minor yet  
noticeable  
problem (2)
Moderate problem,  
interferes some  
daily activities (3)
Major problem,  
interferes with most  
daily activities (4)
Disabling  
problem (5)
Total
Arthralgias
  1–4 4 (13%) 1 (3%) 3 (9%) 11 (34%) 7 (22%) 6 (19%) 32 (100%)
  5–8 3 (9%) 4 (12%) 5 (15%) 6 (18%) 9 (27%) 6 (18%) 33 (100%)
  9–12 1 (4%) 0 (0%) 1 (4%) 9 (32%) 12 (43%) 5 (18%) 28 (100%)
  13–24 3 (8%) 5 (14%) 4 (11%) 7 (19%) 11 (30%) 7 (19%) 37 (100%)
  25–52 5 (18%) 1 (4%) 4 (14%) 6 (21%) 6 (21%) 6 (21%) 28 (100%)
  Total 16 (10%) 11 (7%) 17 (11%) 39 (25%) 45 (28%) 30 (19%) 158 (100%)
Fatigue
  1–4 1 (3%) 0 (0%) 2 (6%) 6 (19%) 15 (47%) 8 (25%) 32 (100%)
  5–8 2 (6%) 1 (3%) 4 (12%) 10 (30%) 9 (27%) 7 (21%) 33 (100%)
  9–12 0 (0%) 1 (4%) 1 (4%) 4 (14%) 8 (29%) 14 (50%) 28 (100%)
  13–24 0 (0%) 1 (3%) 2 (5%) 7 (19%) 13 (35%) 14 (38%) 37 (100%)
  25–52 1 (4%) 0 (0%) 2 (7%) 8 (29%) 10 (36%) 7 (25%) 28 (100%)
  Total 4 (3%) 3 (2%) 11 (7%) 35 (22%) 55 (35%) 50 (32%) 158 (100%)
Myalgias
  1–4 6 (19%) 0 (0%) 4 (13%) 8 (25%) 10 (31%) 4 (13%) 32 (100%)
  5–8 6 (18%) 3 (9%) 6 (18%) 7 (21%) 6 (18%) 5 (15%) 33 (100%)
  9–12 4 (14%) 1 (4%) 3 (11%) 5 (18%) 13 (46%) 2 (7%) 28 (100%)
  13–24 6 (16%) 3 (8%) 7 (19%) 9 (24%) 9 (24%) 3 (8%) 37 (100%)
  25–52 8 (29%) 1 (4%) 0 (0%) 7 (25%) 7 (25%) 5 (18%) 28 (100%)
  Total 30 (19%) 8 (5%) 20 (13%) 36 (23%) 45 (28%) 19 (12%) 158 (100%)
cognition
  1–4 8 (25%) 0 (0%) 1 (3%) 9 (28%) 8 (25%) 6 (19%) 32 (100%)
  4–8 6 (18%) 8 (24%) 3 (9%) 6 (18%) 7 (21%) 3 (9%) 33 (100%)
  8–12 1 (4%) 4 (14%) 5 (18%) 5 (18%) 7 (25%) 6 (21%) 28 (100%)
  12–24 9 (24%) 3 (8%) 5 (14%) 5 (14%) 9 (24%) 6 (16%) 37 (100%)
  24–52 3 (11%) 2 (7%) 4 (14%) 8 (29%) 6 (21%) 5 (18%) 28 (100%)
  Total 27 (17%) 17 (11%) 18 (11%) 33 (21%) 37 (23%) 26 (16%) 158 (100%)
Table 3 changes in symptom severity by follow-up time group, at the time of the last follow-up visit
Time on IV  
treatment
Arthralgias Myalgias Fatigue Cognition
1–4 weeks 1.57 (1.02–2.4), P = 0.04 1.41 (0.95–2.11), P = 0.09 1.44 (0.96–2.17), P = 0.08 1.25 (0.78–1.98), P = 0.35
5–8 weeks 1.49 (0.97–2.29), P = 0.07 1.56 (1.04–2.34), P = 0.03 1.88 (1.25–2.82), P , 0.01 1.35 (0.86–2.12), P = 0.19
9–12 weeks 1.54 (0.94–2.53), P = 0.08 1.52 (0.96–2.4), P = 0.07 1.51 (0.94–2.42), P = 0.09 0.96 (0.57–1.61), P = 0.87
13–24 weeks 1.30 (0.84–2.02), P = 0.24 2.14 (1.41–3.25), P # 0.01 2.12 (1.39–3.23), P , 0.01 1.10 (0.69–1.75), P = 0.69
25–52 weeks 1.57 (0.93–2.66), P = 0.09 2.08 (1.24–3.5), P = 0.01 2.22 (1.32–3.73), P , 0.01 1.97 (1.11–3.48), P = 0.02
Note: Conditional odds ratios (95% confidence intervals) and P values are presented using the first week in treatment as the reference
The findings for fatigue were similar to those for   myalgias, 
with improvement shown in all patient strata, and the most 
improvement occurring in patients on the longest courses of 
intravenous treatment. There was an estimated 22% reduction in 
the proportion of patients reporting disabling fatigue after 
25–52 weeks of treatment compared with baseline.   Significant 
improvement in cognition was only seen in the group on treat-
ment for 25–52 weeks, with an odds ratio of being in a less 
severe symptom group of 1.97 (95% CI: 1.11–3.48) at the 
end of treatment compared with baseline. This   corresponds 
to a 26% decline in the number of patients reporting cogni-
tive problems to be disabling or a major problem at the end 
of treatment compared with baseline.
Discussion
Neurologic Lyme disease is characterized by neuropsychiat-
ric symptoms that may be persistent and difficult to treat.11–14 
Intravenous antibiotic therapy is recommended for this 
condition, but the duration of prescribed treatment is contro-
versial. While the IDSA guidelines recommend a maximum International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
644
Stricker et al
Table 4 Precedents for prolonged antibiotic therapy19,30–34
Disease Organism Treatment Duration
Tuberculosis (drug-sensitive) Mycobacterium tuberculosis 2–4 antibiotics 6–9 months
Tuberculosis (multidrug resistant) Mycobacterium tuberculosis 3–5 antibiotics 18–24 months
Leprosy Mycobacterium leprae 3 antibiotics 24 months
Atypical tuberculosis Mycobacterium chelonae IV + oral antibiotics 6–12 months
Brucella spondylitis Brucella spp. IM + oral antibiotics 6–12 months
complicated actinomycosis Actinomyces spp. IV + oral antibiotics 6–18 months
Whipple’s disease Tropheryma whipplei IV + oral antibiotics 12–24 months
Q fever endocarditis Coxiella burnetii 2 antibiotics 36 months
Alveolar echinococcosis Echinococcus multilocularis Oral antibiotics 5.7 years (mean)
Abbreviations: IV, intravenous; IM, intramuscular.
of 30 days of antibiotic therapy,6 the International Lyme and 
Associated Diseases Society guidelines take a more open-
ended approach, tailoring therapy to resolution of patient 
symptoms.5 Although some studies have shown benefit of 
longer antibiotic therapy in neurologic Lyme disease,13,19 this 
therapy has been considered ineffective and even dangerous by 
IDSA.6–10 However, in a previous safety study, we showed that 
prolonged intravenous antibiotic therapy was associated with 
low morbidity and no mortality in closely monitored patients 
referred for treatment of neurologic Lyme disease.11 The 
mean length of treatment in that study was almost 4 months, 
and while the safety data was reassuring for that length of 
therapy, the study did not address the benefit of treatment 
given to those patients.
The present study evaluated the benefit of prolonged intra-
venous antibiotic therapy in patients diagnosed with neuro-
logic Lyme disease by their treating physicians. The diagnosis 
of neurologic Lyme disease was supported by the symptom 
distribution recorded at baseline in these patients, as shown in 
Table 1. The predominance of women in our study population 
is consistent with previous observations that persistent Lyme 
disease is more commonly diagnosed in women.20 In contrast 
with our previous study, only patients receiving intravenous 
ceftriaxone were included in the analysis. As in the previ-
ous investigation, patients received an average of more than 
3 months of intravenous antibiotic treatment, and they were 
closely monitored by homecare nurses. The treatment was 
associated with low morbidity and no mortality, confirming 
the safety of this therapy, as described previously.11
Previous controlled trials have examined relatively short 
intravenous antibiotic treatments ranging from 1–3 months for 
patients with neurologic Lyme disease.13,21–23 A major criticism 
of these trials is that the length of treatment was insufficient to 
eradicate a persistent spirochetal infection. Our results indicate 
that prolonged antibiotic treatment for 25–52 weeks may be 
required to induce improvement in symptoms of neurologic 
Lyme disease. Although a control group was not included in 
the study, each patient had baseline symptom severity scores 
and multiple longitudinal measurements for up to 1 year, 
and the improvement in fatigue, myalgias, and cognition was 
significant with extended antibiotic therapy.
Numerous studies have documented persistent B. 
  burgdorferi infection in patients with persistent symptoms 
of neurologic Lyme disease following short-course antibiotic 
therapy.1–4 Furthermore, animal models have demonstrated 
that short-course antibiotic therapy may fail to eradicate the 
Lyme spirochete.24–26 Persistent spirochetal infection appears 
to be a more likely explanation for chronic symptoms of 
Lyme disease than the autoimmune hypotheses that have 
been postulated but never substantiated, and recent evidence 
has shed more light on the complex strategies that allow B. 
burgdorferi to evade both the immune response and antibi-
otic agents.27–29 The use of prolonged antibiotic therapy to 
eradicate ongoing spirochetal infection is consistent with 
the evidence for persistent B. burgdorferi infection outlined 
in these studies, and our results support this therapeutic 
approach.
Despite the negative view of prolonged antibiotic treat-
ment for neurologic Lyme disease promoted by IDSA, anti-
biotic therapy ranging from 6 months to more than 5 years is 
recommended by infectious disease experts for a number of 
conditions, including drug-sensitive and drug-resistant tuber-
culosis, leprosy, disseminated atypical mycobacterial disease, 
brucella spondylitis, complicated actinomycosis, Whipple’s 
disease, Q fever endocarditis, and alveolar echinococcosis 
(Table 4).30–34 Furthermore, intravenous antibiotic therapy 
beyond 30 days is routinely prescribed for osteomyelitis,35 
and asplenia or hyposplenia in children is routinely treated 
prophylactically for 3–5 years with oral antibiotics,36,37 while 
daily macrolide therapy for up to 5 years was recently shown 
to prevent exacerbations of chronic obstructive pulmonary 
disease and post-transplant bronchiolitis obliterans.38 Thus, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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in certain conditions, the benefit of long-term therapeutic or 
prophylactic antibiotic therapy is thought to outweigh the 
risk. Our study suggests that prolonged antibiotic therapy 
may be required to improve the most disabling symptoms 
of neurologic Lyme disease, and taken together with 
our   previous safety study, the risks of prolonged antibiotic 
  treatment appear to be justifiable in these patients.
Strengths of this study include the evaluation of significant 
symptoms that are common in neurologic Lyme disease. The 
study included a large number of participants, long duration 
of treatment, and multiple longitudinal measurements per 
participant. This allowed the use of a flexible statistical model 
structure, with separate effects estimated by treatment duration. 
Although the improvements in symptom severity observed in 
this study are encouraging and, in fact, necessary to infer a 
causal relationship between treatment and improvement, the 
lack of randomization into a control or placebo group prevents 
us from confirming a causal relationship. In addition, treatment 
duration was not defined a priori, and nonmedical factors such 
as financial considerations and insurance denial may have influ-
enced treatment duration. These issues need to be addressed in 
a randomized controlled trial with antibiotic therapy adminis-
tered beyond 3 months according to clinical need.
In summary, prolonged intravenous antibiotic therapy is 
associated with improved cognition, fatigue and myalgias in 
patients referred for treatment of neurologic Lyme disease. 
In contrast, improvement in arthralgias did not persist after 
1–4 weeks of therapy. Treatment for 25–52 weeks may be 
necessary to obtain significant symptomatic improvement in 
patients with neurologic Lyme disease.
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